Clermont Pharmaceuticals, Inc., a privately held ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma, yesterday announced positive results from a phase III trial comparing effectiveness of non-preserved latanoprost to Xalatan® (latanoprost ophthalmic solution) 0.005%, in treating patients with elevated intraocular pressure due to open-angle glaucoma.

The non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan, and was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.

Read the full release ^[1].